We may be living in unusual times, but in many respects it is still business as usual for our patients and staff, who are still leading the way in cancer research and treatment globally. Here are some developments you might have missed this month:
Chris O’Brien Lifehouse patient Anthony Barrett spoke to Nine News Sydney about his diagnosis of lung cancer and the promise he’s been given by undergoing immunotherapy. In good news for cancer screening, researchers have developed a new blood test to detect cancer long before symptoms appear.
We recently announced our role in the development of a crucial new blood test, that can show which men with the most aggressive type of prostate cancer should respond to conventional therapy. Urology Times and Medical Xpress both covered the announcement, where you can read more about the science behind this revolutionary test.
Imugene Limited has been given Human Research Ethics Committee approval to commence human trials of its checkpoint immunotherapy candidate, PD1-Vaxx. We are the the first Australian hospital to be granted approval to commence trials on patients, who will begin to be recruited in August. It is designed to treat tumours such as lung cancer, you can read more about Imugene’s work in this field here.
Dr Lisa Horvath spoke at the EAU Annual Congress for 2020 about the treatment of prostate cancers and the promising progress in the use and research of biomarkers in the realm of prostate cancer. A summary of her presentation can be found here.
We are working with OneView to introduce virtual rounding and virtual visitation technology on the tablets provided to inpatients in our wards. This will provide our patients with more ways to connect, more important now than ever due to visiting restrictions during the pandemic.
Macleay Valley resident Wendy Cooper chose to raise money for us by doing Dry July after losing both her brother and sister to cancer in a short time. The funds will help us continue to provide integrated holistic treatment and cancer care to our patients.